Stenting versus drug therapy: comparative study of clinical outcomes in treatment of symptomatic middle cerebral artery stenosis

柳文科; 杨霄鹏

您当前的位置：

首页 >

文章列表页 >

Stenting versus drug therapy: comparative study of clinical outcomes in treatment of symptomatic middle cerebral artery stenosis

更新时间：2026-01-09

- Stenting versus drug therapy: comparative study of clinical outcomes in treatment of symptomatic middle cerebral artery stenosis
- Journal of Army Medical University Vol. 38, Issue 15, Pages: 1788-1791(2016)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  CLC： R651.12;R741.05;R743.4
- Published：2016
- 稿件说明：
移动端阅览
柳文科,杨霄鹏.支架成形术与单纯药物治疗症状性大脑中动脉重度狭窄的临床对比研究[J].陆军军医大学学报(原第三军医大学学报),2016,38(15):1788-1791.

　Liu Wenke,Yang Xiaopeng.Stenting versus drug therapy: comparative study of clinical outcomes in treatment of symptomatic middle cerebral artery stenosis[J].J Amry Med Univ (J Third Mil Med Univ),2016,38(15):1788-1791.
柳文科,杨霄鹏.支架成形术与单纯药物治疗症状性大脑中动脉重度狭窄的临床对比研究[J].陆军军医大学学报(原第三军医大学学报),2016,38(15):1788-1791. DOI：

　Liu Wenke,Yang Xiaopeng.Stenting versus drug therapy: comparative study of clinical outcomes in treatment of symptomatic middle cerebral artery stenosis[J].J Amry Med Univ (J Third Mil Med Univ),2016,38(15):1788-1791. DOI：

摘要

目的评价并比较症状性大脑中动脉狭窄支架成形术与单纯药物治疗的安全性及远期疗效。方法回顾性分析自2009年10月至2015年1月因症状性大脑中动脉严重粥样硬化狭窄（狭窄度超过70%）在我院接受治疗的146例患者的资料，根据患者治疗方案的不同分为支架组67例，药物组79例，患者的临床基线资料、术前术后影像学结果、围手术期并发症情况、临床随访期间不良事件发生情况、影像学复查情况被前瞻性记录并被回顾性分析。结果 ①接受治疗后30 d内支架组4例（6.0%

4/67）发生卒中，包括2例（3.0%，2/67）致死致残性卒中，药物组3例（3.8%

3/79）出现缺血性卒中包括1例（1.3%，1/79）致残性卒中，支架组30 d内卒中及致死致残性卒中发生率略高于药物组，但无统计学差异（P0.05）。②两组所有患者随访（20.8±9.2）个月，30 d后随访期间，支架组共4例（6.2%，4/65）发生治疗侧缺血性卒中，4例均为非致死致残性卒中；药物组共7例（9.0%

7/78）出现治疗侧缺血性卒中，6例（7.7%，6/78）为致残性卒中。两组随访期间总的卒中发生率无统计学差异（P0.05），但支架组致死致残性卒中发生率明显低于药物组（P=0.032）。结论支架成形术治疗大脑中动脉狭窄的安全性较单纯药物治疗稍差，两种治疗手段对卒中预防的总体效果无明显差别，但支架成形术对远期致死致残性卒中的预防效果优于单纯药物治疗。

Abstract

Objective To evaluate and compare the safety and long-term therapeutic efficacy of stenting versus drug therapy in the treatment of symptomatic middle cerebral artery stenosis. Methods A retrospective study of 146 patients with symptomatic middle cerebral artery atherosclerosis stenosis (stenosis 70%) enrolled in the second affiliated hospital of Zhengzhou university from October 2009 to January 2015 was performed. The patients were divided to stenting group (n=67) and drug group (n=79). The data

including patients’ clinical baseline information

imaging of pre- and post-operation

perioperative complications

adverse events during clinical follow-up and outcomes of imaging follow-up

were recorded prospectively and analyzed retrospectively. Results (1) After 30 d of treatment

4 patients (6.0%

4/67) had stroke including 2 cases (3.0%

2/67) of fatal or disabling stroke in the stenting group

whereas 3 patients (3.8%

3/79) occurred ischemic stroke including 1 case (1.3%

1/79) of disabling stroke in the drug group. The risk of stroke including fatal or disabling stroke in the stenting group was slightly higher than that in the drug group

but the difference was not significant (P0.05). (2) The mean follow-up period for all patients was 20.8±9.2 months. After a follow-up of 30 d

4 ipsilateral strokes (6.2%

4/65) occurred in the stenting group

none of which were fatal or disabling strokes; 7 ipsilateral strokes (9.0%

7/78) were found in the drug group

which 6 patients (7.7%

6/78) had disabling strokes. Although the incidence of stroke between the 2 groups was not significant (P0.05)

the occurrence rate of disabling stroke in the stenting group was much lower than that in the drug group (P=0.032). Conclusion The safety of stenting is slightly worse than that of drug therapy in the treatment of symptomatic middle cerebral artery stenosis. The overall effect of the 2 therapeutic regimens on stroke prevention is not significantly different. However

stenting treatment is superior to drug therapy in a long-term prevention of recurrent fatal or disabling stroke.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Construction and verification of a nomogram prediction model for vascular plaque stability in patients with progressive cerebral infarction based on serum MCP-1, MCPIP1 combined with inflammatory factors

Dihydromyricetin ameliorates vascular endothelial damage by inhibiting NLRP3 inflammasome activity through Sirtuin 3

Melatonin inhibits ox-LDL-induced proliferation of vascular smooth muscle cells

Construction of an inflammatory microenvironment-responsive HDL-mimetic nanoparticle and evaluation of its in vitro anti-atherosclerotic activity

GLP-1(7-36) inhibits atherosclerosis progression in ApoE-/- mouse aorta by lowering expressions of CD36 and ACAT1 in foam cells

Related Author

LI Yanda

SONG Yan

CHEN Yalun

LI Xu

WANG Minheng

ZHANG Hui

刘明华

申卉

Related Institution

Department of Neurology， Nanyang Second People’s Hospital， Xinxiang Medical College

⁰